KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Oct 31, 2025. Filed Dec 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Oct 31, 2025 · Filed Dec 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
During the three months ended October 31, 2025, each of Brian Webster, our Chief Executive Officer, and Traci Umberger, our Chief Administrative Officer and General Counsel, adopted a “Rule 10b5-1 trading arrangement”, as such term is defined in Item 408(a) of Regulation S-K. All trading plans that were adopted during the period were entered into during an open insider trading window and are intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, and ourpolicies regarding transactions in our securities.
| Name and Title | Date | Action | Expiration Date | Total Shares Subject to Plan |
|---|---|---|---|---|
| Brian Webster | September 29, 2025 | Adoption | August 31, 2026 | 260,000 |
| Traci Umberger | September 26, 2025 | Adoption | September 29, 2026 | 91,500 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.